We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+26.51%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.37B
AUM Growth
-$51.4M
Cap. Flow
-$112M
Cap. Flow %
-4.71%
Top 10 Hldgs %
45.23%
Holding
88
New
8
Increased
6
Reduced
18
Closed
10

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$105M
2
ZYME icon
Zymeworks
ZYME
+$41.2M
3
IMVT icon
Immunovant
IMVT
+$32.2M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$26.6M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$15.1M

Top Sells

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$76.9M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$73.7M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$43.1M
4
NUVL
Nuvalent
NUVL
+$32.4M
5
EQRX
EQRx, Inc. Common Stock
EQRX
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
51
Verastem
VSTM
$664M
$7.66M 0.32%
1,585,221
-79,334
-5% -$389K
NCEL
52
NewcelX Ltd
NCEL
$19.4M
$7.41M 0.31%
+14,368
New +$4.26M
WHWK
53
Whitehawk Therapeutics
WHWK
$233M
$7.21M 0.3%
562,309
-316,776
-36% -$4.14M
IMA
54
ImageneBio Inc
IMA
$57.8M
$6.66M 0.28%
208,589
– –
ARAV
55
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.32M 0.27%
+4,784,214
New +$6.11M
ELDN icon
56
Eledon Pharmaceuticals
ELDN
$220M
$5.4M 0.23%
2,326,710
– –
PVLA
57
Palvella Therapeutics
PVLA
$2.2B
$5.28M 0.22%
63,504
– –
VIRX
58
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.28M 0.22%
3,614,662
– –
CDTX
59
DELISTED
Cidara Therapeutics
CDTX
$5.19M 0.22%
343,056
– –
LKFT
60
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$4.44M 0.19%
+100,000
New +$4.21M
HLVX
61
DELISTED
HilleVax
HLVX
$4.16M 0.18%
248,579
-133,873
-35% -$2.42M
PYXS icon
62
Pyxis Oncology
PYXS
$279M
$3.94M 0.17%
2,938,851
– –
INFI
63
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$3.53M 0.15%
6,353,645
– –
IVA
64
Inventiva
IVA
$876M
$3.04M 0.13%
686,040
– –
MOLN
65
Molecular Partners
MOLN
$154M
$2.87M 0.12%
443,221
– –
ELEV
66
DELISTED
Elevation Oncology
ELEV
$2.19M 0.09%
2,312,200
– –
MTEM
67
DELISTED
Molecular Templates, Inc.
MTEM
$1.64M 0.07%
333,104
– –
IMUX icon
68
Immunic
IMUX
$141M
$1.61M 0.07%
+114,943
New +$3.13M
RNAC icon
69
Cartesian Therapeutics
RNAC
$240M
$1.57M 0.07%
46,392
– –
CALA
70
DELISTED
Calithera Biosciences, Inc
CALA
$1.52M 0.06%
464,742
– –
XFOR icon
71
X4 Pharmaceuticals
XFOR
$345M
$1.34M 0.06%
44,922
+16,659
+59% +$789K
CRVS icon
72
Corvus Pharmaceuticals
CRVS
$1.05B
$1.17M 0.05%
1,370,947
– –
EOCN
73
Eocene Ltd. Ordinary Shares
EOCN
$3.74M
$870K 0.04%
1,208
-42
-3% -$22K
ELTX icon
74
Elicio Therapeutics
ELTX
$48.1M
$869K 0.04%
107,130
– –
RNTX
75
Rein Therapeutics
RNTX
$62.7M
$561K 0.02%
236,835
-26,443
-10% -$88.8K
1 2
3
4

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q4 2022 Portfolio in Review

As of Q4 2022, BVF Inc held 88 positions worth $2.37B, down 2.1% from $2.42B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

BVF Inc withdrew a net $112M in Q4 2022, closing 10 positions and reducing 18 holdings. Its most notable exit was Relmada Therapeutics, an estimated $76.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, BVF Inc opened a new position in Axsome Therapeutics worth $135M.

  • BVF Inc's largest Q4 2022 buy was Axsome Therapeutics: 1,755,000 shares worth $135M.
  • BVF Inc added most to POINT Biopharma Global Inc. Common Stock in Q4 2022, an estimated $26.6M increase.
  • BVF Inc's biggest Q4 2022 reduction was Ionis Pharmaceuticals, cutting an estimated $73.7M.
  • BVF Inc fully exited Relmada Therapeutics in Q4 2022, selling an estimated $76.9M.
  • BVF Inc's ten largest holdings make up 45% of its $2.37B portfolio in Q4 2022.
  • BVF Inc opened 8 new positions and closed 10 in Q4 2022.
  • BVF Inc's portfolio value fell 2.1% quarter-over-quarter to $2.37B.

Based on BVF Inc's 13F filing for Q4 2022, filed 14 Feb 2023.